

ASX/AIM Announcement

10 April 2025

Wellnex Life secures UK distributor for the Company's international expansion of its innovative brands

Highlights

- Wellnex Life appoints leading UK distributor [Powermed Plus](#) to represent the Company's innovative brands in the lucrative UK market.
- Following the Company's successful admission to the AIM market of the London Stock Exchange (AIM), Wellnex Life is focused on driving growth through international expansion of its brands.
- Recent admission to AIM supports the strategy to increase awareness of the Company and its brands in the lucrative UK market.

Wellnex Life Limited (ASX/AIM: WNX) (**Wellnex Life or Company**) is pleased to announce the appointment of Powermed Plus Limited (**Powermed Plus**) as its distribution partner to take the Company's innovative brands into the large and lucrative UK market.

Wellnex Life has identified opportunities in the UK market for its brands and see this as the next growth phase for the Company. Wellnex Life has identified Powermed Plus as the ideal partner for the UK market to take advantage of the opportunities and accelerate the growth in international marketing and sales of the Company's brands.

Wellnex Life's recent admission to the AIM market of the London Stock Exchange will further increase the awareness of the Company and its brands in the UK market which, the Board believes, will assist the Company in generating sales in the UK market.

Wellnex Life will work closely with Powermed Plus to commence presenting its brands to UK retailers in Q3 2025, with sales planned to commence in 2026.

About Powermed Plus

Powermed Plus is a leading contract healthcare services provider incorporating sales, marketing, distribution and support services into the Pharmacy, Health Food and Grocery sectors in the UK.

Powermed Plus, for over 20 years, has offered tailored business solutions for companies looking to expand their distribution in the UK market, with its strong customer relationships and experienced sales team.

David Mappedoram Managing Director of Powermed Plus said: "Powermed Plus are thrilled with our collaboration with Australian company Wellnex Life. We are eagerly looking forward to the opportunity to introduce Wellnex Life's exciting and innovative brands to the UK market. Together, we aim to enhance the well-being of individuals across the UK with Wellnex Life's exceptional products."

Zack Bozinovski Managing Director Wellnex Life said: "We are thrilled to be able to partner with a quality company such as Powermed Plus to help distribute our innovative and exciting brands throughout the pharmacy and grocery sectors in the UK. During all steps of the selection process, the Powermed Plus team demonstrated a strong alignment to our Company core values and objectives and showed a strong passion towards our brands and their success. Having our brands available to UK consumers, on the back of our UK listing, was a major priority and focus for the Company and we look forward to closely working with David and his team to help execute our brand roll out strategy into major UK retailers."

To stay up to date on company news and announcements, please register your details on the Wellnex Life Limited investor portal: <https://wellnexlife.investorportal.com.au/register/>

This announcement was authorised for release to the market by the board of Wellnex Life Limited.

For further information, please contact:

Australian Investors

Zack Bozinovski
T: +61 3 8399 9419
E: zack.b@wellnexlife.com.au

UK Investors

Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson / Robert Collins

Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)

swykeham@oranacorp.com

Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470
David Hignell / Vadim Alexandre

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGUGDSLXBDGUG